Quarterly report · Q3
4574.TEDINET S100S6X1
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.4bn | 2023-01-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥5.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.4bn | 2022-01-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | −¥444m | 2023-01-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | −¥2.8bn | 2022-01-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | −¥589m | 2023-01-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥3.4bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.9bn | 2022-01-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥537m | 2023-01-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥3.2bn | 2022-01-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥562m | 2023-01-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥4.9bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥3.2bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥562m | 2023-01-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | −¥3.2bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥15.8bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥15.0bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.0bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥7.0bn | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥9.8bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥9.8bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.8bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2022-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-12.09 | 2023-01-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.98 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-112.26 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-72.97 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.8 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 61.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-09-30 | −¥738m |
| jpcrp040300-q3r_E22560-000Infection Control Businessreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥724m |
| jpcrp040300-q3r_E22560-000Infection Control Businessreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥724m |
| jpcrp040300-q3r_E22560-000Infection Control Businessreportable segment | segment profit | 2023-01-01 → 2023-09-30 | −¥643m |
| jpcrp040300-q3r_E22560-000Other Business Linesreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥4m |
| jpcrp040300-q3r_E22560-000Other Business Linesreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥4m |
| jpcrp040300-q3r_E22560-000Other Business Linesreportable segment | segment profit | 2023-01-01 → 2023-09-30 | −¥17m |
| jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥3.7bn |
| jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥3.7bn |
| jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥955m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-09-30 | ¥4.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-09-30 | ¥4.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-09-30 | ¥293m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥893m |
| jpcrp040300-q3r_E22560-000Infection Control Businessreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥976m |
| jpcrp040300-q3r_E22560-000Infection Control Businessreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥976m |
| jpcrp040300-q3r_E22560-000Infection Control Businessreportable segment | segment profit | 2022-01-01 → 2022-09-30 | −¥1.8bn |
| jpcrp040300-q3r_E22560-000Other Business Linesreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥5m |
| jpcrp040300-q3r_E22560-000Other Business Linesreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥5m |
| jpcrp040300-q3r_E22560-000Other Business Linesreportable segment | segment profit | 2022-01-01 → 2022-09-30 | −¥14m |
| jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-09-30 | −¥42m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-09-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-09-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-09-30 | −¥1.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 365
| Item | Context | Value | Unit |
|---|---|---|---|
| Premium allowance of retirement (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |